The impact of automated insulin delivery on glucose management in people with diabetes and advanced chronic kidney disease
Automated insulin delivery safely improved blood sugar control by 13 percentage points in people with diabetes and advanced kidney disease, a group rarely studied.
This 5-site randomized crossover trial (n=40, Australia + Denmark) is the first RCT to demonstrate that automated insulin delivery is both feasible and safe in people with diabetes complicated by advanced chronic kidney disease — a population historically excluded from AID studies. AID produced a 13-percentage-point improvement in time in glucose target range over usual care, without increasing hypoglycemia, representing a clinically meaningful and immediately actionable finding for a high-unmet-need population.
What the study was
- Study design
- Prospective randomized crossover trial
- Population
- Adults with T1D or insulin-treated T2D and advanced CKD (eGFR stage 3b+, including dialysis)
- Sample size
- 40
- Category
- Treatment Innovation
- Maturity
- Potentially Practice-Changing
- Journal
- Diabetologia
Why it surfaced
First RCT of automated insulin delivery in diabetes + advanced CKD — a population typically excluded from AID trials. Strong RCT design (crossover), clinically meaningful primary endpoint met (+13% time-in-range), multi-site international, no safety signals. Directly actionable for nephrologists and diabetologists managing this underserved high-risk population.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.